Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

MLA

Susan N. Chi, et al. Pub Fees Email Yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b5d51f0ad014a0e5d759351e185cfaf4&authtype=sso&custid=ns315887.

APA

Susan N. Chi, Sudha Parasuraman, Jason R. Dobson, Suraj G. Bhansali, Alessandro Matano, Marlyane Motta, Giles W. Robinson, Thomas Cash, Shakeel Modak, Andrew D.J. Pearson, Aurélien Marabelle, Nicholas G. Gottardo, James I. Geller, Matthias Fischer, Steven G. DuBois, Franck Bourdeaut, & Birgit Geoerger. (2023). Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

Chicago

Susan N. Chi, Sudha Parasuraman, Jason R. Dobson, Suraj G. Bhansali, Alessandro Matano, Marlyane Motta, Giles W. Robinson, et al. 2023. “Pub Fees Email Yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b5d51f0ad014a0e5d759351e185cfaf4&authtype=sso&custid=ns315887.